This article is provided for educational and informational purposes only. All compounds discussed are supplied strictly for laboratory and research use. Vitro Labs products are not for human or animal consumption.
Most compounds act on one receptor. CJC-1295 and Ipamorelin act on two. and that’s the whole point of pairing them.
Growth hormone release in mammals is controlled by two upstream signals that come from different places in the brain and use different receptor families. One is GHRH, a hypothalamic compound that tells the pituitary to make and release growth hormone. The other is ghrelin, a stomach-derived compound that binds a separate receptor on the same pituitary cells and amplifies the signal. CJC-1295 mimics the first. Ipamorelin mimics the second. Used together in research models, they engage both arms of the system at the same time.
Teichman and colleagues (2006) reported that CJC-1295 with DAC produced sustained increases in GH and IGF-1 in human research subjects across a 6-to-10-day window (PMID: 16940447). Raun and colleagues (1998) characterized Ipamorelin as a selective GH secretagogue without the cortisol or prolactin response seen with earlier compounds (PMID: 9849822). This research guide reviews how the two compounds work at the receptor level, what preclinical and clinical studies have actually shown, and how researchers think about the pairing in laboratory protocols. for laboratory research use only.
Before getting into the mechanism in detail, here’s what the peer-reviewed literature actually reports about these two compounds.
CJC-1295 is a synthetic 30-amino-acid compound. It’s a modified version of the first 29 residues of native GHRH. the same fragment that GHRH(1-29), or sermorelin, is built on. with four amino acid substitutions that protect it from being chopped up by dipeptidyl peptidase IV (DPP-IV), the enzyme that normally degrades native GHRH within minutes of release.
The four substitutions are at positions 2, 8, 15, and 27. They don’t change the receptor-binding face of the molecule. that’s still recognizable as GHRH to the GHRHR receptor. but they make the compound resistant to enzymatic cleavage. The result is a GHRH analog that lasts much longer in circulation than native GHRH does.
The full “CJC-1295” molecule also carries a small chemical handle called DAC at the C-terminus. DAC is a maleimidopropionic acid linker that forms a covalent bond with cysteine-34 on serum albumin. the most abundant protein in blood. Once the compound is locked onto albumin, it doesn’t get filtered out by the kidneys at the normal rate.
That’s how a compound that would otherwise have a 30-minute half-life ends up circulating for 6 to 10 days (Teichman et al., 2006, PMID: 16940447).
This single design choice. adding the DAC linker. separates the two versions of CJC-1295 you’ll see in the literature. CJC-1295 without DAC (sometimes called “Mod GRF 1-29”) has the four amino acid substitutions but no albumin tether. It survives DPP-IV but still clears from circulation quickly. CJC-1295 with DAC has both.
Ipamorelin is a synthetic 5-amino-acid compound. five amino acids. developed by Novo Nordisk in the 1990s as part of a screening program for selective GH secretagogues. Its sequence (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) bears no resemblance to ghrelin or GHRH on the surface, but functionally it acts as a ghrelin-mimetic: it binds and activates the same receptor ghrelin does.
The unusual amino acids in the sequence. alpha-aminoisobutyric acid (Aib), D-2-naphthylalanine, D-phenylalanine. were chosen specifically to give the molecule receptor selectivity without the off-target activity that plagued earlier ghrelin-mimetics like GHRP-6 and GHRP-2. Those earlier compounds drove GH release but also caused noticeable increases in cortisol, ACTH, and prolactin in research subjects.
Raun’s group at Novo Nordisk reported that Ipamorelin produced a GH response in line with GHRP-6 but did not elevate cortisol, ACTH, or prolactin in either rats or pigs (Raun et al., 1998, PMID: 9849822). That selectivity is the reason Ipamorelin keeps showing up in research protocols 25 years later, while GHRP-6 has largely been replaced.
Ipamorelin’s half-life in research subjects is short. roughly 2 hours. It’s not built for sustained exposure. It’s built for a clean, pulsatile GH release that matches the body’s natural rhythm.
To understand why these two compounds get paired, you have to understand how GH release actually works in mammals. It’s not a one-receptor system.
Growth hormone is made and released by a specialized cell type in the anterior pituitary called the somatotroph. Somatotrophs sit there with two different receptors on their surface, both waiting for signals from elsewhere in the body.
The first receptor is the GHRHR. It’s a G-protein-coupled receptor that responds to GHRH released from the hypothalamus. When GHRH binds, it activates Gs proteins, which activate adenylyl cyclase, which makes cyclic AMP. Cyclic AMP activates protein kinase A. Protein kinase A does two things: it drives transcription of the GH gene (so the cell makes more GH protein over time) and it phosphorylates calcium channels that help release GH that’s already stored in vesicles.
The second receptor is the GHSR-1a, also called the ghrelin receptor. It’s also a G-protein-coupled receptor, but it couples to a different G-protein family. Gq. When ghrelin (or a ghrelin-mimetic like Ipamorelin) binds, Gq activates phospholipase C, which generates inositol trisphosphate (IP₃) and diacylglycerol. IP₃ releases calcium from the endoplasmic reticulum. The calcium spike triggers immediate fusion of GH-containing vesicles with the cell membrane. releasing the GH that’s already sitting in storage.
There’s also a third signal that matters: somatostatin, an inhibitory compound that tells somatotrophs to stop releasing GH. Native GH release is pulsatile because somatostatin and GHRH are released in alternating waves from the hypothalamus. Ghrelin-mimetics like Ipamorelin appear to partially suppress somatostatin tone, which adds a third layer to the synergy. and is part of why combined GHRH-analog + ghrelin-mimetic protocols produce such large GH pulses in preclinical models (Bowers, 1990, PMID: 2107514).
When CJC-1295 binds GHRHR, it does the same thing native GHRH does. just for a lot longer.
Binding activates Gs. Gs activates adenylyl cyclase. Adenylyl cyclase converts ATP into cyclic AMP, which jumps inside the cell as a second messenger. Cyclic AMP binds the regulatory subunits of protein kinase A, freeing the catalytic subunits. Those catalytic subunits then phosphorylate a list of targets: CREB (a transcription factor that drives GH gene expression), L-type calcium channels (which let calcium in to support vesicle fusion), and other regulatory proteins.
Two things matter here. First, the cAMP/PKA pathway is slower than the calcium pathway. It builds GH stores over hours and days. Second, sustained GHRHR activation eventually desensitizes the receptor. which is why the question of pulsatile vs sustained exposure (CJC-1295 without DAC vs with DAC) is biologically meaningful in research models.
Teichman’s 2006 trial gave single subcutaneous doses of CJC-1295 with DAC to healthy adult research subjects and tracked GH and IGF-1 over the following two weeks. Mean GH concentrations were elevated 2- to 10-fold for 6 days after a single dose, with peak elevations at doses around 60 µg/kg.
IGF-1. which is produced downstream when GH binds its own receptor on the liver and other tissues. rose 1.5- to 3-fold and stayed elevated for 9 to 11 days (PMID: 16940447). That’s a very different pharmacokinetic profile from native GHRH, which is gone in minutes.
Ipamorelin’s pathway looks very different on paper, even though both compounds end up doing the same thing. getting somatotrophs to release GH.
When Ipamorelin binds GHSR-1a, Gq activates phospholipase C. PLC hydrolyzes a membrane lipid called PIP₂ into two products: inositol trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ diffuses inside the cell and binds IP₃ receptors on the endoplasmic reticulum, which releases stored calcium. That calcium spike triggers vesicle fusion at the cell membrane. GH that was already packaged and sitting in vesicles gets released immediately.
This pathway is fast. It produces a sharp, time-locked GH pulse. measurable within minutes of administration in research models. It’s also additive with the GHRH-driven cAMP signal, because the two pathways converge on the same intracellular calcium pool but feed it through different mechanisms.
Earlier ghrelin-mimetics like GHRP-6 bound GHSR-1a but also engaged related receptors and signaling pathways in the pituitary and adrenal gland. The result was a GH spike that came with cortisol, ACTH, and prolactin spikes. For research that wants to study GH signaling in isolation, that off-target activity is a problem. it makes it hard to attribute downstream effects to GH specifically.
Raun’s group screened for ghrelin-mimetics that would activate GHSR-1a cleanly without engaging the off-target receptors. Ipamorelin was the result. In their original characterization, Ipamorelin produced a GH response comparable to GHRP-6 in swine models but did not elevate cortisol or ACTH at any tested dose. and prolactin elevation was minimal (PMID: 9849822).
| Property | CJC-1295 (GHRHR) | Ipamorelin (GHSR-1a) |
|---|---|---|
| Native ligand mimicked | GHRH (hypothalamic) | Ghrelin (gastric) |
| G-protein family | Gs | Gq |
| Second messenger | cAMP → PKA | IP₃ → calcium |
| Primary effect on GH | Synthesis + release | Immediate release of stored GH |
| Half-life (with DAC where applicable) | 6–10 days (DAC) / ~30 min (no DAC) | ~2 hours |
| Cortisol/prolactin response | Minimal | Minimal (selective) |
“Ipamorelin releases GH with a potency and efficacy similar to GHRP-6. In contrast to GHRP-6, however, Ipamorelin releases GH in a specific manner, having a similar low potency as GHRH on ACTH and cortisol release.”
, Raun et al. (1998), PMID: 9849822
Here’s where it gets interesting. If you give research models a GHRH analog and a ghrelin-mimetic together, the GH pulse isn’t just bigger. it’s bigger than the sum of the two compounds given alone. That’s the formal definition of synergy, and it’s been observed in the GH-secretagogue literature since the 1980s.
The biological reason for the synergy comes down to three things working at once.
The cAMP pathway (GHRH) and the calcium pathway (ghrelin-mimetic) both end up driving release of GH from the same intracellular vesicle pool. but they get there through different routes. Hitting both pathways at the same time produces a larger calcium signal in the somatotroph than either pathway alone, because the cAMP pathway sensitizes the calcium release machinery while the IP₃ pathway actively triggers it.
⚠️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. CJC-1295 and Ipamorelin are research compounds not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols.
GHRH analogs drive GH synthesis through the CREB transcription factor. Ghrelin-mimetics drive immediate release of stored GH. Combining them means there’s more GH being made (so the storage pool stays full) at the same time that release is being triggered. Over a research protocol, that combination supports larger and more sustained GH pulses than a single-pathway compound can produce.
Ghrelin-mimetic activation appears to suppress somatostatin tone in the hypothalamus. meaning the natural brake on GH release is partially lifted while the gas pedal is being pressed. Bowers reported this effect in his foundational work on GH-releasing compounds (Bowers, 1990, PMID: 2107514), and it’s been replicated across the GH-secretagogue literature since.
A handful of papers form the foundation of what’s known about these two compounds. Here’s what they actually reported.
Teichman’s group conducted a randomized, double-blind, placebo-controlled trial of CJC-1295 with DAC in healthy adult research subjects, published in The Journal of Clinical Endocrinology and Metabolism. Single subcutaneous doses ranging from 30 to 250 µg/kg were administered, and GH and IGF-1 were measured for up to two weeks afterward. Mean GH concentrations rose 2- to 10-fold for at least 6 days.
IGF-1 rose 1.5- to 3-fold and stayed elevated for 9–11 days. The paper established the 6-to-10-day half-life window that’s still cited for the DAC version of the molecule (PMID: 16940447).
The original Ipamorelin paper, published in European Journal of Endocrinology, characterized the compound in rat pituitary cells, anesthetized rats, and conscious pigs. Ipamorelin released GH with efficacy similar to GHRP-6 in all three models, but at doses that elevated GHRP-6 cortisol and ACTH, Ipamorelin did not. The paper concluded that Ipamorelin represented the first ghrelin-mimetic with clean GH selectivity (PMID: 9849822).
Cyril Bowers at Tulane spent the 1980s and 1990s working out the biology of what he called GH-releasing compounds. His 1984 paper established that synthetic compounds could trigger GH release independent of GHRH (PMID: 6432465). His 1990 review consolidated the observation that combining a GHRH analog with a GH-releasing compound produced GH release exceeding the sum of the two alone (PMID: 2107514). The synergy he documented is the conceptual basis for every combined GHRH-analog + ghrelin-mimetic research protocol that’s followed.
Ionescu and Frohman, also in The Journal of Clinical Endocrinology and Metabolism, compared pulsatile versus sustained CJC-1295 exposure in research subjects and reported that pulsatile dosing preserved the natural rhythm of GH release while continuous exposure tended to flatten it. The paper is the foundation for the ongoing methodological debate about whether DAC-modified GHRH analogs (sustained exposure) or non-DAC versions (pulsatile exposure) are the more appropriate research tool for a given experimental question (PMID: 17047022).
Sigalos and Pastuszak published a narrative review of GH-secretagogue safety profiles in Sexual Medicine Reviews, summarizing the available human data on CJC-1295, Ipamorelin, and related compounds. The review noted that the selectivity profile of Ipamorelin distinguished it from earlier GHRPs and supported its use in research protocols where cortisol confounding needed to be minimized (PMID: 29396104).
This is the question that comes up most often in the literature, and it has a clean answer at the mechanism level.
CJC-1295 without DAC has the four DPP-IV-resistant amino acid substitutions but no albumin tether. It clears from circulation in roughly 30 minutes, which is fast enough that pulsatile administration in research protocols produces GH pulses that look something like the natural rhythm.
CJC-1295 with DAC has the same amino acid substitutions plus the maleimidopropionic acid linker that locks the compound onto serum albumin. The serum-albumin-bound compound circulates for 6 to 10 days. GHRHR is being activated continuously over that window.
Continuous receptor activation is biologically different from pulsatile activation. The native GH axis runs on pulses. GHRH is released in waves, with somatostatin filling the gaps. Continuous GHRHR activation eventually desensitizes the receptor and changes downstream signaling in ways that haven’t been fully characterized.
Ionescu and Frohman’s 2006 work suggested that pulsatile CJC-1295 exposure preserved the natural rhythm while sustained exposure flattened it (PMID: 17047022). For research that’s trying to study GH pulse dynamics or downstream effects that depend on pulsatile release, the no-DAC version is the cleaner tool. For research that wants to maintain steady-state elevation of GH and IGF-1 across days, the DAC version is appropriate.
The two versions answer different research questions. They’re not competing products in the literature. they’re complementary tools.
One of the reasons Ipamorelin keeps appearing in combined GH-secretagogue research protocols is the selectivity question. Earlier ghrelin-mimetics. GHRP-6, GHRP-2, hexarelin. all drive GH release, but they also elevate cortisol and prolactin to varying degrees.
For research studying GH-specific effects, cortisol confounding is a methodological problem. Cortisol has its own metabolic effects. If a compound elevates both GH and cortisol, it becomes hard to attribute any observed downstream effect to GH alone.
Raun’s 1998 characterization found that at doses producing GH responses equivalent to GHRP-6, Ipamorelin did not elevate cortisol or ACTH (PMID: 9849822). The mechanism for the selectivity isn’t fully worked out. the receptor (GHSR-1a) is the same one GHRP-6 binds. but the structural differences in the Ipamorelin molecule appear to engage a more selective conformational state of the receptor, producing GH-biased signaling without the same off-target activation.
Hexarelin, by comparison, is structurally similar to GHRP-6 and produces a similar cortisol elevation.
That selectivity is the reason Ipamorelin is the ghrelin-mimetic of choice when researchers want to study the combined GHRH + ghrelin pathway without confounding from the HPA axis.
The handling profile of the two compounds is reasonably well characterized.
Both CJC-1295 (with or without DAC) and Ipamorelin are supplied as lyophilized powder. In lyophilized form, both compounds are stable at refrigerated temperatures for extended periods. Long-term storage benefits from freezer temperatures and protection from light and moisture.
In research protocols, both compounds are reconstituted with bacteriostatic water before any laboratory procedure. The reconstituted solution has a shorter stability window than the lyophilized form and benefits from refrigerated storage and use within a defined timeframe documented per research protocol.
Some research suppliers offer CJC-1295 and Ipamorelin as a co-lyophilized blend in a single vial. From a research-protocol perspective, the blend format simplifies handling. one vial, one reconstitution, one batch ID to track. Researchers should verify the documented ratio and batch-specific identity testing for any blend product. Vitro’s CJC-1295 + Ipamorelin 20mg blend is supplied with batch-specific Certificate of Analysis documentation from Freedom Diagnostics, an ISO-certified independent analytical laboratory.
The combined GHRH-analog + ghrelin-mimetic pathway continues to be an active area of preclinical research. Recent work has focused on three questions.
Computational and physiological work on how pulsatile vs sustained GH-secretagogue exposure shapes downstream IGF-1 signaling has continued through 2024 and 2025. The methodological question Ionescu and Frohman raised in 2006 hasn’t been fully resolved, and recent research has used more sophisticated modeling to characterize what the differences actually mean at the tissue level.
There’s growing preclinical interest in whether GHRHR and GHSR-1a interact at the receptor level. not just at the second-messenger level. Receptor heterodimerization, if it occurs in somatotrophs, would provide an additional mechanism for the observed synergy. The 2024–2026 literature on this question is still preliminary.
IGF-1 is produced by multiple tissues in response to GH binding, not just the liver. Recent work has explored how different patterns of GH exposure (pulsatile vs sustained) shape the relative contributions of hepatic IGF-1 (which drives systemic effects) versus locally-produced IGF-1 in tissues like muscle, tendon, and bone. The combined-pathway question. whether CJC-1295 + Ipamorelin produces a different tissue distribution of IGF-1 response than either compound alone. is an open area of investigation in research models.
The two versions bind the same receptor (GHRHR) and trigger the same second-messenger cascade (cAMP/PKA). The difference is exposure time. CJC-1295 without DAC has four amino acid substitutions that protect it from DPP-IV degradation but clears circulation in about 30 minutes. CJC-1295 with DAC carries an additional maleimidopropionic acid linker that covalently binds serum albumin, extending circulation time to 6–10 days. Teichman et al. (2006) characterized this pharmacokinetic profile in human research subjects (PMID: 16940447). The biological consequence is that the no-DAC version produces pulsatile GHRHR activation while the DAC version produces sustained activation, and the two patterns have different downstream effects on GH pulse dynamics.
Selectivity. Earlier ghrelin-mimetics including GHRP-6 and hexarelin bind GHSR-1a and trigger GH release, but they also elevate cortisol, ACTH, and prolactin. For research protocols studying GH-specific effects, that off-target activation is a confound. Raun et al. (1998) characterized Ipamorelin as the first ghrelin-mimetic with GH-selective activity. producing GH responses comparable to GHRP-6 without elevating cortisol or ACTH in rat or pig models (PMID: 9849822). The structural differences in the Ipamorelin 5-amino-acid compound appear to engage a more selective conformational state of the receptor.
The two receptors sit on the same cell but couple to different G-proteins. GHRHR couples to Gs, which activates adenylyl cyclase, generates cAMP, and activates protein kinase A. driving GH synthesis through CREB and sensitizing calcium release. GHSR-1a couples to Gq, which activates phospholipase C, generates IP3, and releases stored calcium from the endoplasmic reticulum. triggering immediate vesicle fusion. The two pathways converge on the same intracellular calcium pool but feed it through different mechanisms, and ghrelin-mimetic activation also appears to suppress somatostatin tone. The result is GH release that exceeds the sum of either pathway alone, a synergy first documented by Bowers et al. (PMID: 2107514).
Teichman’s group conducted a randomized, double-blind, placebo-controlled trial of single subcutaneous CJC-1295 with DAC doses (30 to 250 µg/kg) in healthy adult research subjects, with GH and IGF-1 measured for up to two weeks afterward. Mean GH concentrations rose 2- to 10-fold for at least 6 days. IGF-1 rose 1.5- to 3-fold and stayed elevated for 9 to 11 days. The paper established the 6-to-10-day pharmacokinetic window that’s cited for the DAC version of the molecule and is the foundational human-subject characterization of CJC-1295 with DAC (PMID: 16940447).
Both compounds bind GHSR-1a, but they appear to stabilize different conformational states of the receptor. GHSR-1a is a G-protein-coupled receptor, and modern receptor pharmacology has shown that different ligands can activate biased signaling. engaging some downstream pathways while sparing others. The structural features that make Ipamorelin distinct (the Aib, D-2-Nal, and D-Phe residues) appear to favor GH-release signaling without engaging the pathways that drive cortisol and ACTH release. The detailed structural basis for this selectivity is still an active area of pharmacology research. Raun et al. (1998) was the first paper to characterize the selectivity profile (PMID: 9849822).
Ipamorelin’s half-life in research subjects is approximately 2 hours. CJC-1295 without DAC has a half-life of about 30 minutes after DPP-IV resistance, and CJC-1295 with DAC circulates for 6 to 10 days due to albumin binding. The mismatch between Ipamorelin’s 2-hour half-life and CJC-1295 with DAC’s multi-day half-life is one of the design considerations in combined research protocols. the GHRH-analog exposure persists for days while the ghrelin-mimetic exposure is shorter, which shapes the temporal pattern of GH release in research models.
⚗️ Research Disclaimer: All content on this page is intended exclusively for licensed researchers, academic institutions, and scientific professionals operating within approved laboratory settings. CJC-1295 and Ipamorelin are research compounds not approved for human clinical use by the FDA or equivalent regulatory authorities. This content does not constitute medical advice, clinical guidance, or a recommendation for use in humans or animals outside of approved research protocols. For laboratory research use only. Not for human consumption.
